ReviewInternational journal of molecular sciences2022

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.

Brigida Anna Maiorano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.